Sanofi Diabetes
YOU ARE HERE
Apidra® insulin glulisine [rDNA origin] injection
For U.S. Residents Only
Start saving on Apidra® through our Mealtime Masters Program! Learn more >>

Select your enrollment options to get started today.

Ready to get signed up? Great. Just check the box(es) below to choose what you'd like to enroll in and answer the quick questions that follow:

Check all that apply to you:

Apidra® No Co-Pay* Savings Card and Mealtime Masters Program
The Apidra® No Co-Pay* Savings Program helps people with diabetes with their Apidra® prescription payments. Activate your card by checking this box and you can get No Co-Pay* on Apidra®. You'll also receive additional information about how to help gain better blood sugar control at mealtime. Certain exclusions and restrictions apply. If you're registering someone under the age of 18, please call 866-390-5622.

Mealtime Masters Program
Mealtime Masters is a program that gives people with diabetes resources and tools they can use to help take control of mealtime. And through our educational—and entertaining—content, we're going to try to do just that. The program includes offers, diabetes friendly recipes, CDE** support, insulin information and much more!

Please fill out the information on the following page(s). The information you provide will be used to enroll you in the offer(s) you have selected above and send you additional communications about APIDRA®, insulin, diabetes, related conditions and products.


By providing information in the enrollment form below, you are providing your consent to participate in the Sanofi US Diabetes Education and Support Program (the “Program”).


Sanofi US respects your interest in keeping your personal information private. Sanofi US will not sell or rent your information to any unauthorized parties or mailing lists. The information you provide will only be used by Sanofi US, its affiliates or contracted service providers (“Sanofi”), to provide you with information and materials made available as part of the Program. This information may include information about diabetes, insulin, related products and health conditions, as well as opportunities to participate in market research performed on behalf of Sanofi. In addition, your information may be used by Sanofi to identify ways to optimize the services provided as part of the Program.


By participating in the Program, you also consent to be contacted by mail, email, phone calls, voice messages, SMS text messages and interactive voice recordings.


You may unsubscribe from the Program at any time by visiting https://unsubscribe.sanofi-aventis.us or by calling 1-800-633-1610.


Mealtime E-Messages Terms and Conditions

Sign up for Mealtime eMessages and get a FREE diabetes education session with a Certified Diabetes Educator** (CDE)
Need more information to help manage your diabetes? With Mealtime Messages, you'll get helpful guidance and useful resources. You can also sign up for a free session with a Certified Diabetes Educator** (CDE) from the Sanofi US Diabetes HELP team. Let Mealtime eMessages help you find a Free CDE Session Near You!

What is the service being offered?
Mealtime eMessages is a program designed to help you manage your diabetes. Through a series of emails and text messages, patients receive tips and advice that they need to continue keeping up a healthy diabetes-friendly diet and lifestyle.

What will I get by enrolling?
By enrolling in Mealtime eMessages, you will receive 11 personalized emails throughout the 10 step process. Additionally, users can also enroll to receive up to 100 text messages containing tips, advice and quick recipes, all chosen to arrive at a specific part of the day: breakfast, lunch or dinner.

How do I enroll?
To enroll, simply visit Apidra.com or text the code found in your doctor's office to xxxxx to receive a confirmation text message.

Is there a fee for this service?
Sanofi US does not charge a fee for this service but message and data rates may apply from your mobile carrier.

How do I cancel this service?
After joining the service you may cancel or opt out at any time by texting STOP to xxxxx.

How do I get additional information?
To receive additional info about Mealtime eMessages on your mobile phone, text HELP to xxxxx or call xxx-xxx-xxxx.

Which cellular carriers are participating in the program?
Participating carriers include AT&T, T-Mobile, Sprint, Verizon Wireless, Alltel, Boost, Nextel, U.S. Cellular, and Dobson.

What is Sanofi's privacy policy?
Sanofi US respects your interest in keeping your personal information private. We will not sell or rent your information to any outside mailing lists. For more information, visit http://privacypolicy.sanofi-aventis.us/

Prescription Apidra® is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes to improve blood sugar control. Apidra® given by subcutaneous injection is usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal.

Apidra® may be infused subcutaneously by external insulin infusion pumps.

Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)

Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you are allergic to any of the ingredients in Apidra®.

Do not share needles, insulin pens or syringes with others. Do NOT reuse needles.

You must test your blood sugar levels while using insulin, such as Apidra®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Apidra® must only be used if the solution is clear and colorless with no particles visible.

Please click here for additional Important Safety Information.

Please click here for Full Prescribing Information for Apidra®.

What is Toujeo®? (insulin glargine injection) 300 Units/mL

Prescription Toujeo® is a long-acting insulin used to control blood sugar in adults with diabetes mellitus.

  • Toujeo® contains 3 times as much insulin in 1 mL as standard insulin (100 Units/mL)
  • Toujeo® is not for use to treat diabetic ketoacidosis
  • Toujeo® should not be used in children
Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Do not take Toujeo® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Toujeo®.

Do not share insulin pens even if the needle has been changed. Do NOT reuse needles.

Before starting Toujeo®, tell your doctor about all your medical conditions, including:

  • If you have liver or kidney problems
  • If you are pregnant or planning to become pregnant
  • If you are breast-feeding or planning to breast-feed

Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Toujeo®.

Tell your doctor if you have any new or worsening symptoms of heart failure, including:

  • Shortness of breath
  • Swelling of your ankles or feet
  • Sudden weight gain

Your treatment with TZDs and TOUJEO® may need to be changed or stopped by your healthcare provider if you have new or worsening heart failure.

Tell your doctor about all the medications you take, including over-the-counter medicines, vitamins, and supplements, including herbal supplements.

Toujeo® should be taken once a day at the same time each day to lower blood glucose. You must test your blood sugar levels daily while using any insulin, including Toujeo®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. You should always verify that you have the correct insulin before each injection. Your dose for Toujeo® may be different from other insulins you have taken. Any change of insulin should be made cautiously and only under medical supervision.

Do NOT dilute or mix Toujeo® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Toujeo® must only be used if the solution is clear and colorless with no particles visible.

While using Toujeo®, do not drive or operate heavy machinery until you know how Toujeo® affects you. You should not drink alcohol or use other medicines that contain alcohol.

The most common side effect of any insulin, including Toujeo®, is low blood sugar (hypoglycemia), which may be serious and can be life-threatening. Severe hypoglycemia may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision. Toujeo® may cause serious side effects that can lead to death, such as severe allergic reactions that affect the whole body. Get medical help right away if you have:

  • A rash over your whole body
  • Trouble breathing
  • Shortness of breath
  • Fast heartbeat
  • Swelling of your face, tongue, or throat
  • Sweating
  • Extreme drowsiness, dizziness, or confusion

Toujeo® may have additional side effects. Other possible side effects may include swelling, weight gain, and low potassium.

Injection site reactions are also possible and may include change in fat tissue at the injection site, skin thickening, redness, swelling, and itching.

Toujeo® SoloStar® is a disposable prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.

Click here for Full Prescribing Information for Toujeo®

US.GLU.15.02.008

Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)

Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you are allergic to any of the ingredients in Apidra®.

Do not share needles, insulin pens or syringes with others. Do NOT reuse needles.

You must test your blood sugar levels while using insulin, such as Apidra®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Apidra® must only be used if the solution is clear and colorless with no particles visible.

Apidra®, when given by injection under the skin, should not be mixed with insulins other than NPH. Do not mix Apidra® with any insulin when used in the pump or for intravenous administration.

The most common side effect of insulin, including Apidra®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may include low blood potassium, injection site reactions, such as changes in fat tissue at the injection site, and allergic reactions, such as itching and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

Tell your doctor about other medicines, especially ones commonly called TZDs (thiazolidinediones), and supplements you are taking because they can change the way insulin works. Before starting Apidra®, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed. If you have heart failure or other heart problems, it may get worse while you take TZDs with Apidra®.

It is important to always follow the instructions provided with your Apidra® prescription for use with an external insulin infusion pump. These instructions may differ from the instructions that accompany your insulin infusion pump. Failure to follow the Apidra® specific instructions may lead to serious side effects.

You must change the infusion set (reservoir, tubing, and catheter), and the Apidra® in the pump reservoir at least every 48 hours. Do not mix Apidra® with any insulin when used in the pump and do not dilute Apidra®.

If the pump or infusion set does not work right or in case of handling errors, you may not get the right amount of insulin. This can cause low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), high amounts of sugar and ketones in your blood (ketosis) or a build-up of acid in your blood because your body is breaking down fat instead of sugar (diabetic ketoacidosis). It is important to have another way to inject Apidra® in case the pump does not work.

Apidra® has not been studied in children with type 2 diabetes or in children younger than 4 years of age with type 1 diabetes. In a clinical study of children with type 1 diabetes, there was a higher rate of severe symptomatic hypoglycemia in the two treatment groups (Apidra® or insulin lispro) compared to adult trials with type 1 diabetes.

Apidra® SoloSTAR® is a disposable prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.

Indications and Usage for Apidra® (insulin glulisine [rDNA origin] injection)


Prescription Apidra® is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes to improve blood sugar control. Apidra® given by subcutaneous injection is usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal.

Apidra® may be infused subcutaneously by external insulin infusion pumps.

Click here for Full Prescribing Information for Apidra®.

What is Toujeo®? (insulin glargine injection) 300 Units/mL

Prescription Toujeo® is a long-acting insulin used to control blood sugar in adults with diabetes mellitus.


  • Toujeo® contains 3 times as much insulin in 1 mL as standard insulin (100 Units/mL)
  • Toujeo® is not for use to treat diabetic ketoacidosis
  • Toujeo® should not be used in children

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Do not take Toujeo® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Toujeo®.

Do not share insulin pens even if the needle has been changed. Do NOT reuse needles.

Before starting Toujeo®, tell your doctor about all your medical conditions, including:


  • If you have liver or kidney problems
  • If you are pregnant or planning to become pregnant
  • If you are breast-feeding or planning to breast-feed

Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Toujeo®. Tell your doctor if you have any new or worsening symptoms of heart failure, including:


  • Shortness of breath
  • Swelling of your ankles or feet
  • Sudden weight gain

Your treatment with TZDs and TOUJEO® may need to be changed or stopped by your healthcare provider if you have new or worsening heart failure.

Tell your doctor about all the medications you take, including over-the-counter medicines, vitamins, and supplements, including herbal supplements.

Toujeo® should be taken once a day at the same time each day to lower blood glucose. You must test your blood sugar levels daily while using any insulin, including Toujeo®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. You should always verify that you have the correct insulin before each injection. Your dose for Toujeo® may be different from other insulins you have taken. Any change of insulin should be made cautiously and only under medical supervision.

Do NOT dilute or mix Toujeo® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Toujeo® must only be used if the solution is clear and colorless with no particles visible.

While using Toujeo®, do not drive or operate heavy machinery until you know how Toujeo® affects you. You should not drink alcohol or use other medicines that contain alcohol.

The most common side effect of any insulin, including Toujeo®, is low blood sugar (hypoglycemia), which may be serious and can be life-threatening. Severe hypoglycemia may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision. Toujeo® may cause serious side effects that can lead to death, such as severe allergic reactions that affect the whole body. Get medical help right away if you have:


  • A rash over your whole body
  • Trouble breathing
  • Shortness of breath
  • Fast heartbeat
  • Swelling of your face, tongue, or throat
  • Sweating
  • Extreme drowsiness, dizziness, or confusion

Toujeo® may have additional side effects. Other possible side effects may include swelling, weight gain, and low potassium.

Injection site reactions are also possible and may include change in fat tissue at the injection site, skin thickening, redness, swelling, and itching.

Toujeo® SoloStar® is a disposable prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.

Click here for Full Prescribing Information for Toujeo®.


Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. It should be taken once a day at the same time each day to lower blood glucose.

Do not use Lantus® to treat diabetic ketoacidosis.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Do not take Lantus® if you are allergic to insulin or any of the inactive ingredients in Lantus®.

Do not share needles, insulin pens or syringes with others. Do NOT reuse needles.

You must test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.

Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus® must only be used if the solution is clear and colorless with no particles visible.

Tell your doctor about other medicines, especially ones commonly called TZDs (thiazolidinediones), and supplements you are taking because they can change the way insulin works. Before starting Lantus®, tell your doctor about all your medical conditions including if you have heart failure or other heart problems, liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed. If you have heart failure, it may get worse while you take TZDs with Lantus®.

The most common side effect of insulin, including Lantus®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may include swelling, weight gain, injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash. In rare cases, some allergic reactions may be life threatening.

Click here for Full Prescribing Information for Lantus®.

Click here for information on Sharps Medical Waste Disposal.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.



The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

*Offer is not valid for patients if their prescriptions are paid in part or full by any state or federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA, DOD, or TriCare. Offer is not valid where prohibited by law. Sanofi US reserves the right to rescind, revoke, or amend this offer without notice. Maximum benefit is $100 off per prescription depending on your out of pocket costs for the duration of the program.

**"Certified Diabetes Educator" and "CDE" are certification marks owned and registered by the National Certification Board for Diabetes Educators (NCBDE). NCBDE is not affiliated in any way with Sanofi US (or your official designation). NCBDE does not sponsor or endorse any diabetes-related products or services.